Addex Therapeutics

About Addex Therapeutics

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Products & Services

Dipraglurant (mGlu5 NAM):Targeted for Post-Stroke and Traumatic Brain Injury (TBI) recovery.

ADX71149 (mGlu2 PAM):Under research and development for undisclosed indications.

GABAB PAM - Substance Use Disorder:Focused on treatment for substance use disorders.

GABAB PAM - Chronic Cough:Developed for the treatment of chronic cough.

Specialties

Allosteric Modulators Neurological Disorders Small Molecule Drugs allosteric modulators neurological disorders

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: ATM Offering T: - FT: ATM Offering	A: 3300000 MR: - FA: up to $3.3 million FAN: 3300000	D: 2025-12-11 FD: 2025-12-11	1 investors
2	RT: At-the-Market Offering T: - FT: At-the-Market Offering	A: 2100000 MR: - FA: up to $2.1 million FAN: 2100000	D: 2024-01-31 FD: 2024-01-31	1 investors
3	RT: Grant T: - FT: Grant	A: 4000000 MR: - FA: €4 million FAN: 4000000	D: 2023-09-20 FD: 2023-09-20	1 investors
4	RT: Collaboration Funding T: - FT: Collaboration Funding	A: 2970000 MR: - FA: CHF 2.7 million FAN: 2970000	D: 2023-08-03 FD: 2023-08-03	1 investors
5	RT: Equity T: - FT: Equity	A: 5000000 MR: - FA: $5.0 million FAN: 5000000	D: 2023-04-05 FD: 2023-04-05	1 investors
6	RT: Equity Financing T: - FT: Equity Financing	A: 5000000 MR: - FA: 5.0 million FAN: 5000000	D: 2023-04-03 FD: 2023-04-03	1 investors

ATM Offering Latest

2025-12-11

$3.3M

1 investor (Pro only)

At-the-Market Offering 2024-01-31

$2.1M

Grant 2023-09-20

$4.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Tim Dyer

Co-Founder, Board Director and Chief Executive Officer

R

Roger Mills

Board Director and Chief Medical Officer

M

Mikhail Kalinichev

Head of Translational Science

L

Lénaïc Teyssédou

Head of Finance

V

Vincent Lawton

Chairman of the Board of Directors

J

Jake Nunn

Director

View 13 more team members with Pro

Unlock Full Team Directory

Recent News